CoChat
Cited by 199

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

Chi, Andrew S., Tarapore, Rohinton S., Hall, Matthew D., Shonka, Nicole, Gardner, Sharon, Umemura, Yoshie, Sumrall, Ashley, Khatib, Ziad, Mueller, Sabine, Kline, Cassie, Zaky, Wafik, Khatua, Soumen, Weathers, Shiao-Pei, Odia, Yazmin, Niazi, Toba N., Daghistani, Doured, Cherrick, Irene, Korones, David, Karajannis, Matthias A., Kong, Xiao-Tang, Minturn, Jane, Waanders, Angela, Arillaga-Romany, Isabel, Batchelor, Tracy, Wen, Patrick Y., Merdinger, Krystal, Schalop, Lee, Stogniew, Martin, Allen, Joshua E., Oster, Wolfgang, Mehta, Minesh P. · 2019 · Journal of Neuro-Oncology

Abstract

H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven medical therapies. The entity predominantly occurs in children and young adults. ONC201 is a small molecule selective antagonist of dopamine receptor D2/3 (DRD2/3) with an exceptional safety profile. Following up on a durable response in the first H3 K27M-mutant diffuse midline glioma patient who received ONC201 (NCT02525692), an expanded access program was initiated. Patients with H3 K27M-mutant gliomas who received at least prior radiation were eligible. Patients with leptomeningeal spread were excluded. All patients received open-label ONC201 orally once every week. Safety, radiographic assessments, and overall survival were regularly assessed at least every 8 weeks by investigators. As of August 2018, a total of 18 patients with H3 K27M-mutant diffuse midline glioma or DIPG were enrolled to single patient expanded access ONC201 protocols. Among the 18 patients: seven adult (> 20 years old) and seven pediatric (< 20 years old) patients initiated ONC201 with recurrent disease and four pediatric patients initiated ONC201 following radiation, but prior to disease recurrence. Among the 14 patients with recurrent disease prior to initiation of ONC201, median progression-free survival is 14 weeks and median overall survival is 17 weeks. Three adults among the 14 recurrent patients remain on treatment progression-free with a median follow up of 49.6 (range 41–76.1) weeks. Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progression-free for at least 53 and 81 weeks. Radiographic regressions, including a complete response, were reported by investigators in a subset of patients with thalamic and pontine gliomas, along with improvements in disease-associated neurological symptoms. The clinical outcomes and radiographic responses in these patients provide the preliminary, and initial clinical proof-of-concept for targeting H3 K27M-mutant diffuse midline glioma with ONC201, regardless of age or location, providing rationale for robust clinical testing of the agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11060-019-03271-3

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 199

Metadata

Authors
Chi, A. S., Tarapore, R. S., Hall, M. D., Shonka, N., Gardner, S., Umemura, Y., Sumrall, A., Khatib, Z., Mueller, S., Kline, C., Zaky, W., Khatua, S., Weathers, S.-P., Odia, Y., Niazi, T. N., Daghistani, D., Cherrick, I., Korones, D., Karajannis, M. A., Kong, X.-T., Minturn, J., Waanders, A., Arillaga-Romany, I., Batchelor, T., Wen, P. Y., Merdinger, K., Schalop, L., Stogniew, M., Allen, J. E., Oster, W., & Mehta, M. P.
Venue
Journal of Neuro-Oncology
Published
2019-08-27
Volume
145
Issue
1
Pages
97-105
ISSN
  • 0167-594X (ISSN-L)
  • 1573-7373
OpenAlex
W2971333398
Cited by
199
References
3
FWCI
10.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.